China’s Ad5-nCoV COVID-19 Vaccine Granted Conditional Marketing Authorization
This week, the China National Medical Products Administration (NMPA) granted conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 […]
This week, the China National Medical Products Administration (NMPA) granted conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 […]
CanSino Biologics, one of China’s leading vaccine makers, inked a deal with Pakistan’s government to sell the Ad5-nCoV vaccine candidate […]
Mexico was active recently in the investigational vaccine market, securing two deals with two different companies for a total of […]
Pakistan, the fifth most populous nation in the world, recently geared up to support a Phase 3 COVID-19 vaccine clinical […]
The World Health Organization (WHO) now purportedly considers China as its strategic COVID-19 vaccine supplier as the world’s most populous […]
Indonesia is preparing to support the commercialization of CanSino Biologics’ Ad5-nCoV vaccine candidate as Solution Biologics Sdn Bhd (SOLBIO), a […]
According to local reports out of Russia (Moscow Times), the Phase 3 clinical trial investigating Cansino Biologics’ COVID-19 vaccine candidate, […]
As seven vaccines worldwide have moved to the final stages of testing (e.g. Phase 3 clinical trials), four of them […]
Canada has finally made the call to terminate the CanSino Biologics Ad5-nCoV clinical trial, the nation’s first such study targeting […]
Although TrialSite has already reported that the Canadian government has gone to a “Plan B” for COVID-19 vaccines, the issue […]